Vitamin E and Reduced Alkaline Phosphatase Level

Doses used in studies

Time to effect

Median: 8.6 weeks · IQR 8.6 weeks–8.6 weeks · Range 8.6 weeks–8.6 weeks — Reported in 1 of 1 study

Safety in these studies

all-cause mortalityNo significant differenceSerious adverse eventRR 3.45, 95% CI 0.57 to 20.86
The effects of vitamin E versus placebo or no intervention on all-cause mortality (risk ratio (RR) 3.45, 95% confidence interval (CI) 0.57 to 20.86; 3 trials, 351 participants; very low certainty evidence) and serious adverse events (RR 1.91, 95% CI 0.30 to 12.01; 2 trials, 283 participants; very low certainty evidence) are very uncertain.
from: Vitamin E for people with non-alcoholic fatty liver disease.
serious adverse eventsNo significant differenceSerious adverse eventRR 1.91, 95% CI 0.30 to 12.01
The effects of vitamin E versus placebo or no intervention on all-cause mortality (risk ratio (RR) 3.45, 95% confidence interval (CI) 0.57 to 20.86; 3 trials, 351 participants; very low certainty evidence) and serious adverse events (RR 1.91, 95% CI 0.30 to 12.01; 2 trials, 283 participants; very low certainty evidence) are very uncertain.
from: Vitamin E for people with non-alcoholic fatty liver disease.
Overall tolerabilityReported
The effects of vitamin E versus placebo or no intervention on physical health-related quality of life ... and non-serious adverse events (RR 0.86, 95% CI 0.64 to 1.17; 2 trials, 283 participants; very low certainty evidence) are also very uncertain.
from: Vitamin E for people with non-alcoholic fatty liver disease.

1 of 1 paper

Vitamin E for people with non-alcoholic fatty liver disease.